Allogene Therapeutics (ALLO) Financials

$1.76

$0.03 (1.73%)

As on 10-Sep-2026 16:14EDT

Market cap

$681 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

--

P/B Ratio

1.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	4.64	--	0.02	0.10	0.24	38.49
Cost of Revenue	37.09	12.36	13.64	14.20	16.73	13.07
Gross Profit	-32.45	-12.36	0.02	0.10	0.24	38.49
Operating Expenses	147.87	194.57	273.22	327.83	335.69	294.28
Operating Profit (EBIT)	-180.32	-206.93	-273.20	-327.74	-335.45	-255.79
Other Income	--	--	--	--	--	-1.21
Profit before Tax	-165.49	-190.89	-257.15	-327.27	-332.63	-257.01
Provision for Tax	--	--	0.44	-2.82	-2.82	-12.17
Profit after Tax (Net Income)	-165.49	-190.89	-257.59	-327.27	-329.82	-244.84
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-332.63	-257.01

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	436.18	292.54	422.18	512.23	666.88	925.20
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	82.19	90.85	91.01	93.53	100.97	77.72
Current Liabilities	31.73	32.51	35.52	37.08	53.73	47.91
Total Liabilities	581.82	415.91	548.71	642.84	821.58	1,050.83

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	210.09	158.16	245.32	183.72	292.76	579.51
Current Assets	340.00	257.75	303.39	459.12	528.82	471.32
Total Assets	890.09	415.91	548.71	642.84	821.58	1,050.83
Total Debt*	70.35	83.25	90.76	95.12	101.12	73.13
Net Current Assets	--	225.24	267.86	422.04	474.31	423.15

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-149.25	-200.30	-237.73	-220.52	-184.81
Cash Flow from Investing Activities	--	95.56	75.69	163.29	106.16	163.66
Cash from Financing Activities	--	30.16	116.68	95.70	2.95	11.96
Net Cash Inflow / Outflow	--	--	--	--	--	-9.19

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.67	-0.87	-1.22	-1.94	-2.29	-1.76
Cash EPS ($)	--	-0.81	-1.16	-1.86	-2.19	-1.68
Adjusted Book Value ($)	--	1.33	2.00	3.04	4.63	6.65
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.68	-0.95	-1.41	-1.53	-1.33
Free Cash Flow per Share ($)	--	-0.68	-0.95	-1.42	-1.57	-1.48

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-42.96	-45.99	-47.59	-37.34	-22.97
ROE (%)	-45.42	-53.42	-55.13	-55.51	-41.43	-24.42
ROA (%)	-23.77	-39.58	-43.24	-44.70	-35.23	-21.49
EBIT Margin (%)	-3,538.66	--	-1,168,027.27	-344,489.47	-138,044.86	-664.58
Net Margin (%)	-3,566.68	--	-1,170,863.64	-344,489.47	-135,726.34	-656.82
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	21,190.91	-1.00	-0.77	-0.61	-0.99	0.00
EBIT Growth (%)	30.39	26.13	21.48	2.44	-31.14	0.95
Net Profit Growth (%)	30.14	25.90	21.29	0.77	-34.71	-4.87
EPS Growth (%)	39.78	0.29	0.37	0.15	-0.30	0.02
Book Value Growth (%)	-15.75	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-1.58	-1.74	-1.65	-2.75	-8.48
Price / Book Value	1.58	1.03	1.06	1.05	1.36	2.24
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.04	-0.76	-1.01	-0.60	-1.53	-6.90
Close Price ($)	2.08	1.37	2.13	3.21	6.29	14.92
High Price ($)	4.46	3.78	5.78	8.44	17.49	39.12
Low Price ($)	0.98	0.86	1.78	2.23	5.56	12.90
Market Cap ($ Cr)	680.62	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.28	0.21	0.19	0.15	0.08
Short term debt to equity ratio	--	0.03	0.02	0.01	0.01	0.00
Current Ratio	10.72	7.93	8.54	12.38	9.84	9.84
Quick Ratio	10.72	--	--	14.07	11.00	10.26
Interest Coverage	-126.30	-176.57	-1,419.70	-19.12	-19.60	-24.47

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	8,636.36	1,789.47	1,358.02	15.59
Asset Turnover	0.01	--	0.00	0.00	0.00	0.03
Receivable days	--	--	29,884.09	9,611.84	6,989.35	41.75
Inventory Days	--	--	-1,672.43	-1,606.47	-900.37	-3,173.45
Payable days	--	142.80	151.19	254.50	263.60	288.58
Cash Conversion Cycle	--	--	28,060.48	7,750.88	5,825.38	-3,420.28

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.